1. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L (1999) Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5: 2884–2890
2. Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, Raymond E, Maddox A-M, Kaye SB, Kieback DG, Harris A, Ochs J (2000) Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumour types: evidence of good tolerability. Proc Am Soc Clin Oncol 19: 177a 686
3. Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placeido S, Bianco AR, Ciardiello F (2000) Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res 6: 4343–4350
4. Caraglia M, Pinto A, Correale P, Zagonel V, Genua G, Leardi A, Pepe S, Bianco AR, Tagliaferri P (1994) 5-Aza-2′-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. Ann Oncol 5: 269–276
5. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47: 943–946